Janssen Pharmaceutica NV   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Beerse Belgium (1953)
Status: Acquired by Johnson and Johnson (1961)

Organization Overview

First Clinical Trial
1995
NCT00249145
First Marketed Drug
1958
chlorzoxazone (parafon forte dsc)
First NDA Approval
1958
chlorzoxazone (parafon forte dsc)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Jannsen Pharmaceutica | Janssen Asia-Pacific Medical Affairs | Janssen Biologics BV | Janssen Biologics B.V. | Janssen Biotech, Inc. | Janssen-Cilag A.G., Switzerland | Janssen Cilag N.V./S.A. | Janssen Cilag Pharmaceutica S.A.C.I., Greece | Janssen Cilag S.A.S. | Janssen Diagnostics, LLC | Janssen, GlaxoSmithKline (GSK) | Janssen Inc. | Janssen Infectious Diseases BVBA | Janssen Korea Ltd. | Janssen Korea, Ltd | Janssen Korea, Ltd. | Janssen Korea, Ltd., Korea | Janssen, LP | Janssen, L.P. - Investigator Initiated Studies Program | Janssen Medical Affairs | Janssen-Ortho Inc., Canada | Janssen-Ortho LLC | Janssen Pharmaceutica | Janssen Pharmaceutical Companies of Johnson & Johnson | Janssen Pharmaceutical K.K. | Janssen Pharmaceuticals | Janssen Pharmaceuticals Inc | Janssen Pharmaceutica NV | Janssen Pharmaceutica N.V. | Janssen Pharmaceutica N.V., Belgium | Janssen Pharmaceutica, Philippines | JANSSEN PHARMS | Janssen R&D Ireland | Janssen R&D, L.L.C. | Janssen Research & Development | Janssen Research & Development L.L.C | Janssen Research & Development, LLC | Janssen Research & Development, L.L.C | Janssen Research & Development, L.L.C. | Janssen Sciences Ireland UC | Janssen Scientific Affairs, LLC | Janssen Services, LLC | Janssen Services, L.L.C. | Janssen Vaccines & Prevention B.V.